Ullem Scott B.'s Form 4 filing
Edwards Lifesciences Corp (EW) · filed Feb 28, 2025
- Accession no.
- 0001225208-25-002619
- Filed
- Feb 28, 2025
- Trade date
- Feb 28, 2025
- Filing delay
- Same day
- Rule 10b5-1 plan
- Checked
This filing lists 3 non-derivative transactions and 1 derivative transaction. Open-market sales total $796.4K. It was filed on the trade date.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Ullem Scott B.CIK 0001446989 | Officer (CVP, Chief Financial Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 28, 2025 | Common Stock | MOption exerciseAcquired | +11,250 | $45.28 | +$509,400 | 41,637 | Direct | |
| Feb 28, 2025 | Common Stock | SSaleDisposed | −3,490 | $71.38F2 | −$249,116.2 | 38,147 | Direct | |
| Feb 28, 2025 | Common Stock | SSaleDisposed | −7,760 | $70.52F3 | −$547,235.2 | 30,387 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 28, 2025 | Common Stock | MOption exerciseDisposed | −11,250 | $0.00 | $0 | 22,500 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
This transaction was executed in multiple trades at prices ranging from $71.23 to $71.69. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 1 transaction in Table I.
- F3
This transaction was executed in multiple trades at prices ranging from $70.20 to $71.06. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 1 transaction in Table I.
Remarks
This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.